Thank You Med-X Investors
Our latest investment round is now closed. To find out about new opportunities to invest and to get updates on our growth, just join below.
HIGHLIGHTS
Top 3 Reasons to Invest in Med-X
1. Rapid
Growth
200%
revenue growth in 5 years, from $647K in 2018 to $1.89M in 2023.
2. World-Class Partners
.avif)
3. Nasdaq Here We Come
Meet MXRX
We’re planning a direct listing on the Nasdaq, and we’ve already reserved the ticker symbol "MXRX.” This is a rare opportunity to invest before it happens.
PROBLEM
Long-term Pesticide Exposure Linked to Human Diseases2
The negative effects caused by widespread pesticide use can be more dangerous as the pests themselves. The world is demanding a change. People and farmers desperately need safer, effective, alternative solutions to preserve food supplies and protect public health from pests but without the risks.
SOLUTION
Simpler, Safer, More Effective Pesticides
More than addressing just one issue with a “green” product, we’ve developed and refined a portfolio of proprietary plant-based products. Third-party studies prove our flagship Nature-Cide pesticides outperform chemical-based products.
Proven Effectiveness
Third-Party Independent Study proves Nature-Cide outperforms traditional synthetic vector control products using only essential oils from Clove, Cottonseed, Cedar, and Cinnamon.
No Chemicals
Our solutions are safe around children, pets, and the environment.
Complete Solution
One product line manages multiple pests in all settings. Less need to carry dozens of products for an operator. Same cost to use all-natural solutions.
200% Revenue Growth In 5 Years
The market wants our green solutions. We’ve consistently grown revenue year-over-year, from $647K in 2018 to $1.89M in 2023, 200% in total1. And we continue to form strategic partnerships across the value chain, including collaborations with key wholesale distributors.
Our Global Vision Is a $17.6B Opportunity
We’ve secured an exclusive agreements with Target Specialty Products, Ensystex and Preserve to introduce the Nature-Cide product line into 41 new markets, including but not limited to:
- Australia
- New Zealand
- Southeast Asia
- Caribbean Islands
- Africa
- Mexico
- And more
The global biopesticide market is expected to grow ~3X by 2030, from $5.8 billion in 2022 to an impressive $17.6 billion by 20301. We expect pesticide bans and other regulatory actions around the world to fuel our vision of Nature-Cide as the world’s leading “clean” pest control product.
- Direct Listing to the Nasdaq
- Export to Mexico, Central America, and the Caribbean.
- Acquire multiple profitable Nature-Cide product suppliers.
- Export to all of Southeast Asia and the Pacific Islands.
- Acquire like-minded businesses in the wellness and pest control industries that have similar distribution relationships as us.
- Export to Australia, New Zealand, South Africa, Canada, Middle East, and Africa.
- Start the Registration process in the EU.
- Expand the service division through M&A and become a “Top 100 Pest Control Company” in the US.
Our Roadmap for Growth
Once we list and get access to growth capital, management plans to launch its M&A strategy to bolster capitalization after the public market listing process1.
Watch Our Investor Q&A
Watch our most recent replay to gain valuable insights into our company and this exciting investment opportunity. This is a fantastic chance to learn directly from our leadership team and understand our vision and strategy. Stay tuned for future webinars where you can participate in live Q&A sessions and get your questions answered in real time.
UPDATES
Recent News
Med-X Partners with Anasac Ambiental for Nature-Cide Product Distribution in South America
Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities
Med-X to Showcase a Newly Developed Nature-Cide Rat & Mouse Control Product at PestWorld 2024 in Denver Colorado from October 22-25
Med-X Announces Registration of the Nature-Cide All-Purpose Commercial Concentrate Product in Mexico
Experienced Leadership Team
Operations Professional, Oversaw over $200M Revenue Book in Prior Role.
Clinical Investigator for Big Pharma and Family Physician for more than 24 years.
Finance Professional with Over 35 Years of Public Company Experience.
E-Commerce Professional with Significant Experience Scaling Companies.
Project Management and Human
Resources Professional.
Internal and Osteopathic Medicine.
Neurologist and Scientist.
Financial and Investment
Banking Specialist
Scientist and Mathematician.